Dr. Naidoo Discusses Biomarker Testing for Checkpoint Inhibitors

Jarushka Naidoo, MD, BCh
Published: Sunday, Mar 24, 2019



Jarushka Naidoo, MBBCh, assistant professor of oncology, John Hopkins University, discusses the application of biomarker testing for use of checkpoint inhibitors in patients with cancer.

Nadioo says that there are agents are now approved in 13 or more different cancer types; however, biomarker testing depends on the cancer type and at which stage the patient is at in their disease. PD-L1 testing via immunohistochemistry is one of the most extensive biomarker tests to be done.

Different companies utilize different antibodies to test for this particular biomarker, says Naidoo. For instance, different cell populations can be used to define PD-L1 activity, she concludes. 

<<< 2019 NCCN Annual Meeting


Jarushka Naidoo, MBBCh, assistant professor of oncology, John Hopkins University, discusses the application of biomarker testing for use of checkpoint inhibitors in patients with cancer.

Nadioo says that there are agents are now approved in 13 or more different cancer types; however, biomarker testing depends on the cancer type and at which stage the patient is at in their disease. PD-L1 testing via immunohistochemistry is one of the most extensive biomarker tests to be done.

Different companies utilize different antibodies to test for this particular biomarker, says Naidoo. For instance, different cell populations can be used to define PD-L1 activity, she concludes. 

<<< 2019 NCCN Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x